Edward Jordan
Corporate Officer/Principal chez XSPRAY PHARMA AB
Fortune : - $ au 31/05/2024
Profil
Edward P.
Jordan is currently the Chief Commercial Officer at Xspray Pharma AB since 2023.
Prior to this, he was the Chief Commercial Officer at Humanigen, Inc. from 2020 to 2023 and Senior Vice President at DBV Technologies, Inc. from 2016 to 2020.
He also held a senior leadership position at AMAG Pharmaceuticals, Inc. Mr. Jordan has an undergraduate degree from the University of Rhode Island and an MBA from Southern New Hampshire University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
HUMANIGEN INC
0,01% | 11/04/2023 | 12 500 ( 0,01% ) | - $ | 31/05/2024 |
Postes actifs de Edward Jordan
| Sociétés | Poste | Début |
|---|---|---|
| XSPRAY PHARMA AB | Corporate Officer/Principal | 15/09/2023 |
Anciens postes connus de Edward Jordan
| Sociétés | Poste | Fin |
|---|---|---|
| HUMANIGEN, INC. | Corporate Officer/Principal | 14/09/2023 |
DBV Technologies, Inc.
 DBV Technologies, Inc. Medical/Nursing ServicesHealth Services Part of DBV Technologies SA, DBV Technologies, Inc. provides medical care services. The company is based in New York, NY. | Corporate Officer/Principal | 24/08/2020 |
| AMAG PHARMACEUTICALS, INC. | Sales & Marketing | - |
Formation de Edward Jordan
| University of Rhode Island | Undergraduate Degree |
| Southern New Hampshire University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| HUMANIGEN, INC. | Health Technology |
| XSPRAY PHARMA AB | Health Technology |
| Entreprise privées | 2 |
|---|---|
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
DBV Technologies, Inc.
DBV Technologies, Inc. Medical/Nursing ServicesHealth Services Part of DBV Technologies SA, DBV Technologies, Inc. provides medical care services. The company is based in New York, NY. | Health Services |
